Fermenta Biotech Ltd

Ms. Preeti Thakkar, a Promoter of Fermenta Biotech Limited, has sold 11,65,938 equity shares, representing 3.96% of the total shareholding, in the open market on September 28, 2026. Following this sale, her total holding in the company has reduced from 7.61% to 3.65%. The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The total equity share capital of the company remains Rs. 14,71,54,935, divided into 2,94,30,987 equity shares of Rs. 5/- each.

Fermenta Biotech Ltd has announced the closure of its trading window for all directors, promoters, insiders, designated persons, and auditors. This closure is effective from October 01, 2026, and will remain in effect until 48 hours after the announcement of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. During this period, no trading or dealing in the company's securities is permitted by these individuals or their immediate relatives. The specific date of the board meeting to approve the financial results will be communicated separately.

Fermenta Biotech Limited has entered into an exclusive license agreement with Vellore Institute of Technology (VIT) for a novel Vitamin B12 fortification technology. This technology enables natural in-situ enrichment of Vitamin B12 during the fermentation process for common foods like curd, idli/dosa batters, and breads. The collaboration aims to address Vitamin B12 deficiency, particularly among vegetarian and vegan populations, by making fortified foods a more accessible source. The technology, covered by Indian Patent Application No. 202441015300, demonstrated approximately 80% retention of enhanced Vitamin B12 levels post-cooking in laboratory studies. Fermenta Biotech plans to advance this technology towards practical, market-ready applications, leveraging its expertise in vitamins and food fortification. The commercial potential spans FMCG, food and nutrition, and nutraceutical sectors.

Fermenta Biotech Ltd announced the voting results of its 74th Annual General Meeting (AGM) held on August 11, 2026. All resolutions presented to the shareholders, including the adoption of financial statements, declaration of dividend, appointment of a director, and approval of related party transactions, received overwhelming support. The voting was conducted through remote e-voting and electronic voting at the AGM, with a scrutineer appointed to oversee the process. The results indicate strong shareholder confidence in the company's management and financial performance.

Fermenta Biotech Ltd presented its performance at its 74th Annual General Meeting, highlighting a year of "operating momentum, renewed strategic conviction, and capital commitment." The company reported a record consolidated revenue of ₹548 crore for FY26, a 14% increase from FY25's ₹481 crore. Core EBITDA, excluding real estate, surged 44% to ₹120 crore, with a Profit After Tax (PAT) of ₹70 crore. Key achievements include the grant of a plant-source Vitamin D3 process patent, EDQM CEP for D3 100 SD, and approval for ₹110 crore in new Dahej capacity. The company also noted ten consecutive quarters of positive results across its three operating businesses, emphasizing innovation, scale, and focus in its strategy.

Fermenta Biotech Ltd reported unaudited Q1FY27 consolidated revenue of INR 126.2 crore, flat quarter-on-quarter (QoQ) and down 13% year-on-year (YoY). EBITDA stood at INR 22.4 crore, down 39% YoY and 11% QoQ. Profit After Tax (PAT) declined significantly by 56% YoY to INR 9.5 crore, impacted by non-recurring items in the previous year's comparable quarter. Human nutrition volumes saw an 18% QoQ increase, and the Indian market's contribution rose to 47% of consolidated revenue. The company highlighted growth in Other APIs and Intermediates, and Green Chemistry Solutions/Enzymes.

Fermenta Biotech Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results on August 11, 2026. The company also submitted the Limited Review Reports from M/s. SRBC & Co. LLP, Chartered Accountants, who provided an unmodified opinion on the financial results.

Fermenta Biotech Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated results. The company also submitted the Limited Review Reports from its statutory auditors, M/s. SRBC & Co. LLP, who provided an unmodified opinion. The Board meeting took place on August 11, 2026.

Fermenta Biotech Limited announced the successful listing of its 2,94,30,987 equity shares on the National Stock Exchange of India Limited (NSE) effective August 4, 2026. The shares will trade under the symbol FERMENTA and ISIN INE225B01021. This dual listing on both NSE and BSE (where it has been listed since 1977 under Scrip Code 506414) aims to increase accessibility for a wider investor community, enhance visibility, and facilitate more efficient price discovery. The company, a leading manufacturer of Vitamin D3 API and other nutritional ingredients, views this as a significant milestone in its 75-year journey, reflecting its growth and expanding global customer base.

Fermenta Biotech Limited announced that its existing 2,94,30,987 equity shares will be listed and admitted for trading on the National Stock Exchange of India Limited (NSE) effective August 4, 2026. The company's symbol on NSE will be 'FERMENTA'. This listing follows NSE's approval and is in compliance with SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The shares will be of Rs. 5/- each, fully paid up, with distinctive numbers ranging from 1 to 29430987. The market lot is set at 1, and there are no lock-in details applicable. This move expands the company's accessibility to a wider investor base on a major stock exchange.